- Monoclonal Antibodies
- Interferons
- Interleukins
- Vaccines
- Others (e.g., JAK inhibitors, TNF inhibitors)
Immunology Pharmaceuticals Market size was valued at USD 91.63 billion in 2023 and is expected to grow at a 10.2% CAGR from 2024 to 2030. Immunology pharmaceuticals are medications used to treat various autoimmune and inflammatory disorders. The increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease is expected to drive the growth of the immunology pharmaceuticals market over the forecast period. In addition, advancements in biotechnology and a growing understanding of the immune system are anticipated to boost market growth significantly. Technological innovations in drug development, including the rise of targeted therapies and personalized medicine, are revolutionizing immunology treatments. For instance, in December 2022, Sanofi received FDA approval for Enjaymo (sutimlimab-jome), a first-in-class humanized monoclonal antibody for the treatment of cold agglutinin disease (CAD) in adults. This drug is the first and only approved treatment for CAD, a rare type of autoimmune hemolytic anemia.
Enjaymo works by inhibiting the classical complement pathway, specifically targeting C1s, which is a novel mechanism of action for treating this condition. However, the market faces certain challenges, including the high cost of biologics and stringent regulatory requirements. Patent expirations of key drugs and the subsequent entry of biosimilars also pose potential threats to market growth. Despite these obstacles, the market presents numerous opportunities, particularly in emerging markets with large untapped patient populations. The development of new therapeutic approaches, such as CAR-T cell therapies for autoimmune diseases, offers promising avenues for market expansion. Current trends in the immunology pharmaceuticals market include a shift towards subcutaneous and oral formulations for improved patient convenience, increasing focus on combination therapies, and growing interest in the gut microbiome's role in immune-mediated diseases. The rise of artificial intelligence in drug discovery and increasing collaborations between pharmaceutical companies and biotech firms are shaping the future of immunology drug development.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The immunology pharmaceuticals market is primarily driven by significant factors such as the increasing prevalence of autoimmune and inflammatory disorders and advances in biologic therapies. The rising incidence of conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease is creating a sustained demand for effective immunology treatments. This trend is further amplified by growing awareness and improved diagnostic capabilities, leading to earlier detection and treatment of these conditions. Simultaneously, technological innovations in biologic drug development are revolutionizing immunology therapies. The advent of targeted biologics, including monoclonal antibodies and cytokine inhibitors, has dramatically improved treatment outcomes for many patients. These advanced therapies offer more precise targeting of disease pathways, potentially reducing side effects and improving quality of life for patients with chronic immune-mediated conditions.
The Immunology Pharmaceuticals Market was valued at USD 91.63 billion in 2023 and is expected to grow at a 10.2% CAGR from 2024 to 2030.
The Immunology Pharmaceuticals market is segmented based on type, application, end-user, and geography.
The leading players in the global Immunology Pharmaceuticals market include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Sanofi S.A., and Eli Lilly and Company.
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation, and a seven-year forecast is presented from 2024 to 2030.
1.Executive Summary |
2.Global Immunology Pharmaceuticals Market Introduction |
2.1.Global Immunology Pharmaceuticals Market - Taxonomy |
2.2.Global Immunology Pharmaceuticals Market - Definitions |
2.2.1.Type |
2.2.2.Application |
2.2.3.End User |
2.2.4.Region |
3.Global Immunology Pharmaceuticals Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Immunology Pharmaceuticals Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Immunology Pharmaceuticals Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Interferons |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Interleukins |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Vaccines |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others (e.g., JAK inhibitors, TNF inhibitors) |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Immunology Pharmaceuticals Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Rheumatoid Arthritis |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Psoriasis |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Crohn's Disease |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Multiple Sclerosis |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others (e.g., Lupus, Asthma) |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Immunology Pharmaceuticals Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Specialty Clinics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Immunology Pharmaceuticals Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Immunology Pharmaceuticals Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Monoclonal Antibodies |
9.1.2.Interferons |
9.1.3.Interleukins |
9.1.4.Vaccines |
9.1.5.Others (e.g., JAK inhibitors, TNF inhibitors) |
9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Rheumatoid Arthritis |
9.2.2.Psoriasis |
9.2.3.Crohn's Disease |
9.2.4.Multiple Sclerosis |
9.2.5.Others (e.g., Lupus, Asthma) |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Specialty Clinics |
9.3.3.Pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Immunology Pharmaceuticals Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Monoclonal Antibodies |
10.1.2.Interferons |
10.1.3.Interleukins |
10.1.4.Vaccines |
10.1.5.Others (e.g., JAK inhibitors, TNF inhibitors) |
10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Rheumatoid Arthritis |
10.2.2.Psoriasis |
10.2.3.Crohn's Disease |
10.2.4.Multiple Sclerosis |
10.2.5.Others (e.g., Lupus, Asthma) |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Specialty Clinics |
10.3.3.Pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Immunology Pharmaceuticals Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Monoclonal Antibodies |
11.1.2.Interferons |
11.1.3.Interleukins |
11.1.4.Vaccines |
11.1.5.Others (e.g., JAK inhibitors, TNF inhibitors) |
11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Rheumatoid Arthritis |
11.2.2.Psoriasis |
11.2.3.Crohn's Disease |
11.2.4.Multiple Sclerosis |
11.2.5.Others (e.g., Lupus, Asthma) |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Specialty Clinics |
11.3.3.Pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Immunology Pharmaceuticals Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Monoclonal Antibodies |
12.1.2.Interferons |
12.1.3.Interleukins |
12.1.4.Vaccines |
12.1.5.Others (e.g., JAK inhibitors, TNF inhibitors) |
12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Rheumatoid Arthritis |
12.2.2.Psoriasis |
12.2.3.Crohn's Disease |
12.2.4.Multiple Sclerosis |
12.2.5.Others (e.g., Lupus, Asthma) |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Specialty Clinics |
12.3.3.Pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Immunology Pharmaceuticals Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Monoclonal Antibodies |
13.1.2.Interferons |
13.1.3.Interleukins |
13.1.4.Vaccines |
13.1.5.Others (e.g., JAK inhibitors, TNF inhibitors) |
13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Rheumatoid Arthritis |
13.2.2.Psoriasis |
13.2.3.Crohn's Disease |
13.2.4.Multiple Sclerosis |
13.2.5.Others (e.g., Lupus, Asthma) |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Specialty Clinics |
13.3.3.Pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG |
14.2.2.Pfizer Inc. |
14.2.3.Hoffmann-La Roche Ltd |
14.2.4.Sanofi S.A. |
14.2.5.Novo Nordisk A/S |
14.2.6.Bayer AG |
14.2.7.Takeda Pharmaceutical Company Limited |
14.2.8.Bluebird Bio, Inc. |
14.2.9.Bristol-Myers Squibb Company |
14.2.10.CSL Limited |
15. Research Methodology |
16. Appendix and Abbreviations |